Press "Enter" to skip to content

Bayer faces second trial over alleged Roundup cancer risk

Bayer AG is set to face a second U.S. jury over allegations that its popular glyphosate-based weed killer Roundup causes cancer, six months after the company’s share price was rocked by a $289 million verdict in California state court.

Also Read:   Congolese girl, 9, dies of Ebola in Uganda: hospital official